Baltimore-Washington Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,502	Closed	-$486K	–	139
2020 Q2	$486K	Sell	20,502 -625	-3%	-$13.8K	0.07%	90
2020 Q1	$380K	Sell	21,127 -8,723	-29%	-$183K	0.07%	95
2019 Q4	$708K	Sell	29,850 -9,173	-24%	-$223K	0.1%	86
2019 Q3	$1.07M	Sell	39,023 -6,010	-13%	-$178K	0.18%	81
2019 Q2	$1.49M	Buy	45,033 +420	+0.9%	+$14.4K	0.25%	75
2019 Q1	$1.56M	Buy	44,613 +6,874	+18%	+$256K	0.27%	75
2018 Q4	$1.25M	Sell	37,739 -3,891	-9%	-$167K	0.26%	70
2018 Q3	$2.1M	Buy	+41,630	New	+$2.06M	0.38%	62

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Baltimore-Washington Financial Advisors's SUPN Position: Q3 2020 in Review

Baltimore-Washington Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 20,502 shares — an estimated $486K sold.

Baltimore-Washington Financial Advisors first reported a position in SUPN in Q3 2018 and held it in 8 quarters. The position peaked at $2.1M in Q3 2018. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

Baltimore-Washington Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Baltimore-Washington Financial Advisors sold 20,502 Supernus Pharmaceuticals shares in Q3 2020, an estimated $486K.
Baltimore-Washington Financial Advisors first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Baltimore-Washington Financial Advisors's Supernus Pharmaceuticals position peaked at $2.1M in Q3 2018.
209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q3 2020, filed 3 Nov 2020.